当前位置: X-MOL 学术Mater. Today › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
The current status of biodegradable stent to treat benign luminal disease
Materials Today ( IF 24.2 ) Pub Date : 2017-11-01 , DOI: 10.1016/j.mattod.2017.05.002
Yueqi Zhu , Kai Yang , Ruoyu Cheng , Yi Xiang , Tianwen Yuan , Yingsheng Cheng , Bruno Sarmento , Wenguo Cui

Stent implantation is a well-accepted alternative to treat benign luminal disease (BLD). Current stents are often fabricated from plastic, mental and biodegradable materials, and the latter two have wider clinical application. Self-expanding plastic and mental stents possessed many disadvantages such as stent migration, tissue hyperplasia, in-stent restenosis and are difficult to remove, which catalyzes the development of biodegradable stent (BDS). In fact, BDS are not required to be removed upon implementation and leaves no residues in tissue after complete biodegradation compared to metallic or plastic stents. In vascular system, BDS, also termed bioresorbable vascular scaffold (BVS) have also been used to treat luminal stenotic or occlusive lesions in cardiovascular system, peripheral arteries system and veins. In nonvascular system, BDS, with either bare or covered designs, was employed for the treatment of occlusion, stenosis, anastomosis, leak, fistula or perforation of digestive (esophagus, gastrointestinal, biliary, pancreatobiliary, hepatobiliary), respiratory (airway), and urinary (ureteral, urethral). However, the weak radial force, in-stent thrombosis and restenosis become main issues of BDS or BVS and restrict its further clinical application. Therefore, more intensive researches are expected on the strengthening of the radial force of BDS and development of novel drug eluting techniques on its surface to prevent thrombus or restenosis. In this review it is given an updated outline of the use of BDS to treat BLD in a minimal invasive way and explore its advantages and disadvantages for a vast range of fields ranging from cardiovascular to digestive and urinary system. Further discussion to foster the investigation and development of this approach in clinical is also provided.

中文翻译:

可生物降解支架治疗良性管腔疾病的现状

支架植入是治疗良性管腔疾病 (BLD) 的一种广为接受的替代方法。目前的支架多由塑料、金属和可生物降解材料制成,后两者具有更广泛的临床应用。自膨式塑料和金属支架存在支架移位、组织增生、支架内再狭窄、难以取出等诸多缺点,促进了生物可降解支架(BDS)的发展。事实上,与金属或塑料支架相比,BDS 在实施时不需要去除,并且在完全生物降解后不会在组织中留下任何残留物。在血管系统中,BDS,也称为生物可吸收血管支架(BVS)也被用于治疗心血管系统、外周动脉系统和静脉的管腔狭窄或闭塞病变。在非血管系统中,BDS,采用裸露或覆盖设计,用于治疗消化道(食道、胃肠道、胆道、胰胆道、肝胆道)、呼吸道(气道)和泌尿道(输尿管、尿道)的闭塞、狭窄、吻合、渗漏、瘘管或穿孔. 然而,微弱的径向力、支架内血栓形成和再狭窄成为BDS或BVS的主要问题,限制了其进一步的临床应用。因此,在加强BDS的径向力和开发其表面药物洗脱技术以防止血栓或再狭窄方面需要进行更深入的研究。在这篇综述中,它提供了使用 BDS 以微创方式治疗 BLD 的最新概述,并探讨了其在从心血管到消化系统和泌尿系统等广泛领域的优缺点。
更新日期:2017-11-01
down
wechat
bug